At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
VX-864 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects
In Brief
A Phase 2 clinical trial evaluating VX-864 and Placebo for Alpha1-Antitrypsin Deficiency. Completed, enrolled 44 participants across 30 sites in 6 countries.
Detailed Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlpha1-Antitrypsin Deficiency
CountriesCanada, Germany, Ireland, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartJul 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedJul 16, 2020
Enrollment StartJul 24, 2020
Primary CompletionMay 4, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.0 years ago
Interventions
VX-864drug
Tablets for oral administration.
Placebodrug
Placebo matched to VX-864 for oral administration.